Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC
Links shared publicly online about this topic.
- 38total visits
Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.
View full resource at news-medical.net
Tags: Non-Small Cell Lung Cancer, Lung, Diet and Nutrition, Drug, FDA, Pfizer, Nature
Most Recently Shared on August 29, 2011 at 12:31 pm By:
Oncology News: Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC: The U.S. Foo... http://t.co/qC8liZ4
Also Shared By:
Advertisement
News-Medical.Net
@NewsMedical
Pfizer, Abbott receive FDA approval for Xalkori, Vysis ALK FISH test to treat NSCLC: The U.S. Food and Drug Admi... http://t.co/6umNI8D
1 year ago...